Key result
Guidelines recommend intensive LDL-C lowering to under ~/dL for very high-risk secondary prevention.
Why the study?
Recent European and US multisociety guidelines emphasize lowering LDL-C to reduce cardiovascular risk, creating a need to synthesize the abundance of new evidence and perspectives on established and emerging LDL-C-lowering agents.
This review summarizes recent European and US guidelines for lipid management in secondary prevention, emphasizing aggressive LDL-C lowering and the role of newer agents like PCSK9 inhibitors and bempedoic acid.
Answers are grounded in this paper and cite their sources.
Endorses intensive LDL-C targets in very high-risk secondary prevention; leaves open optimal implementation and newer agent outcomes.
Elevated low-density lipoprotein cholesterol (LDL-C) is a principally modifiable cause of atherosclerotic cardiovascular disease; accordingly, recent European and US multisociety dyslipidaemia guidelines emphasise the importance of lowering LDL-C to reduce cardiovascular risk. This review provides perspectives on established and emerging agents that reduce LDL-C to help providers synthesize the abundance of new evidence related to prevention of cardiovascular disease. We provide hypothetical cases of patients with different cardiovascular risk factors and medical histories to illustrate application of current lipid-lowering guidelines in various clinical settings. As a core focus of preventive therapy, both European and US lipid management guidelines emphasise the importance of identifying patients at very high cardiovascular risk and treating to achieve LDL-C levels as low as possible, with European guidelines setting a goal of <1.4 mmol/L (<55 mg/dL) in patients with very high-risk cardiovascular disease. The proprotein convertase subtilisin/kexin type 9 inhibitors are now included in the guidelines and may fulfil an important unmet need for very high-risk patients who are not able to achieve LDL-C goals with conventional agents. The recently approved bempedoic acid and other promising agents under development will add to the armamentarium of lipid-lowering drugs available for clinicians to help patients meet their treatment goals.
No takes yet. Share an insight, caveat, or question.
Atar et al. (2021) conducted a review in Dyslipidaemia and atherosclerotic cardiovascular disease (secondary prevention). Lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, icosapent ethyl) vs. Conventional lipid-lowering monotherapy or placebo was evaluated on Target LDL-C goal achievement in very high-risk patients. European and US dyslipidaemia guidelines recommend intensive LDL-C lowering to <1.4 mmol/L and <1.8 mmol/L, respectively, in very high-risk secondary prevention patients.
Synapse has enriched 10 related papers. Consider them for comparative context: